This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Classical hemophilia고전적 혈우병 (전형혈우병)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D66 | Special Copayment Reduction: V009 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsClassical hemophilia, typical hemophilia, hereditary factor VIII deficiency, hemophilia type A, Classical haemophilia, Hemophilia A, Factor VIII deficiency
C. Adult onsetLikelihood of first onset in adulthood: not low — 'classical hemophilia' was historically the term for all hemophilia before type B was distinguished, and is now used as a synonym for hemophilia A (FVIII deficiency); mild cases are often first diagnosed in adulthood after surgery·trauma.
1. HistoryNarrative centered on historical context: Talmud (5th century) → al-Zahrawi (10th century) → Otto 1803 → Nasse 1820 → Biggs 1952 A/B classification → 1984 F8 cloning → 2022 gene therapy
2. CausesFVIII deficiency due to pathogenic variants in the F8 gene (Xq28); X-linked recessive inheritance; historical meaning of the name 'classical'
3. GeneticsF8 gene 186 kb, 26 exons; intron 22·1 inversions, more than 2,000 pathogenic variants including point mutations·deletions·insertions
4. General epidemiology1 per 5,000~10,000 males; 80% of all hemophilia; about 2,400 in the Korean KBDR
5. PathophysiologyFVIII deficiency → loss of intrinsic tenase complex function → impaired FX activation → reduced thrombin generation → impaired fibrin clotting
6. SymptomsSevere: spontaneous hemarthrosis·muscle hematoma·intracranial hemorrhage; moderate: excessive bleeding after trauma; mild: delayed hemostasis after surgery·tooth extraction
7. SignsIsolated APTT prolongation, normal PT, reduced FVIII:C; correction on mixing study; findings of hemarthrosis
8. ScreeningProlonged APTT → FVIII:C measurement → vWF differentiation; carrier screening and newborn testing when there is a family history
9. DiagnosisAPTT → mixing → FVIII:C → vWF differentiation → Bethesda inhibitor → F8 genetic testing
10. TreatmentDDAVP (mild), FVIII concentrates, emicizumab, fitusiran, gene therapy, inhibitor management
11. PrognosisWith modern prophylaxis, life expectancy approaches normal; inhibitors (25~30% of severe cases) are the key prognostic variable
12. PreventionPrimary prophylaxis (started in infancy), emicizumab, genetic counseling, prenatal·preimplantation diagnosis, lifestyle adjustment
13. ReferencesWFH Guidelines for the Management of Haemophilia, 3rd ed. … and 9 other papers

1. History

The name 'Classical hemophilia' was given because, in the long history of hemophilia, this disease was the first type to be known, and it is now used as a complete synonym for hemophilia A (coagulation factor VIII, FVIII deficiency). Behind this name lies a history of medical observation and inquiry spanning thousands of years.

The oldest written records are found in the Talmud of the 2nd~5th centuries AD. The Yevamot and Hullin tractates of the Talmud describe a rule that if two brothers who had been circumcised died of bleeding, the next brother could be exempted from circumcision. This is the first record showing empirical recognition that the bleeding tendency appears only in males and is transmitted through the maternal line, a remarkable observation that, from the perspective of modern genetics, accurately captured the characteristics of X-linked recessive inheritance.

Abu al-Qasim al-Zahrawi (Abulcasis, 936~1013), a leading physician and surgeon of the 10th-century Islamic Golden Age, described in his medical encyclopedia Al-Tasrif males of a family who died because bleeding could not be stopped even after minor injuries. He clearly described that this bleeding tendency appeared only in males within certain families, strongly implying that it was a hereditary disease. As an Arabic medical description of hemophilia that preceded European medicine, this is of great historical significance.

The systematic description in modern medicine was made in 1803 by John Conrad Otto (1774~1844) of Philadelphia, USA. In his paper "An account of an hemorrhagic disposition existing in certain families," he was the first to clearly describe, in the language of modern medicine, that this disease manifests only in males and is transmitted through females. He traced this family and described a typical X-linked inheritance pattern across 3 generations, and this paper is recognized as the starting point of the modern medical description of hemophilia. In 1820, Johann Lucas Nasse of Germany systematized Otto's observations and established Nasse's law: "this disease manifests only in males but is transmitted by healthy females."

In 1828, the German physician Johann Lukas Schönlein first gave this disease the Greek-derived name 'Hämophilie (hemophilia)'. Until this time, 'hemophilia' was recognized as a single undifferentiated disease, and the hemophilia of this period corresponds to today's 'classical hemophilia', i.e., hemophilia A. In 1937, Patek and Taylor of the United States first described 'antihemophilic factor (AHF)', the substance lacking in the plasma of hemophilia patients, and subsequent studies confirmed it to be coagulation factor VIII (FVIII).

The decisive turning point in classification came in 1952. Rosemary Biggs's research team at the University of Oxford in the UK discovered, in several patients including a boy named Stephen Christmas, a new form of hemophilia in which APTT was prolonged even though the then-known antihemophilic factor (FVIII) was normal. They named this new coagulation factor 'Christmas factor', i.e., coagulation factor IX (FIX), and called the disease caused by its deficiency 'Christmas disease'. With this discovery, 'hemophilia' was for the first time divided into type A (classical, FVIII deficiency) and type B (Christmas disease, FIX deficiency). The modifier 'classical' was attached to distinguish the already known form (FVIII-deficient hemophilia) from the newly discovered type B.

Entering the era of molecular biology, in 1964 Judith Graham Pool discovered that FVIII is present at high concentrations in cryoprecipitate, enabling the first practical concentrate treatment, and in 1984 Wood's research team first cloned the F8 gene. The history of treatment, continuing with approval of recombinant FVIII products in 1992, emicizumab in 2017, and AAV-based gene therapy in 2022, symbolizes entry into an entirely new treatment era thousands of years after the name 'classical hemophilia' was given.

2. Causes

Classical hemophilia is an X-linked recessive genetic disorder caused by deficiency or functional reduction of coagulation factor VIII (FVIII) due to pathogenic variants in the F8 gene. The modifier 'classical' indicates that, historically, it was the form referred to as 'hemophilia' as a whole before hemophilia B (FIX deficiency) was discovered, i.e., before 1952, and it is now used as a synonym for hemophilia A.

Under X-linked recessive inheritance, males (XY) carrying a pathogenic F8 variant develop the disease because they have no normal X chromosome, whereas females carrying one variant (XX, carriers) mostly do not develop it because the F8 gene on the remaining normal X chromosome produces sufficient FVIII. However, in carrier females in whom the normal X chromosome is predominantly inactivated through random X-chromosome inactivation (lyonization), FVIII activity can be considerably reduced; such cases are called symptomatic carriers.

Spontaneous (de novo) mutations occur in about 30% of patients with classical hemophilia, in which case the disease develops even without a family history. These are cases in which a new F8 variant arose in the germ cells of the grandparent or parent generation. 'Acquired hemophilia A' due to acquired FVIII inhibitors is a separate disease with an entirely different mechanism from congenital classical hemophilia, and is classified under a different code (D68.3) in the ICD-10 system.

3. Genetics

The F8 gene is located at the distal end of the long arm of the X chromosome (Xq28) and, with a total length of about 186 kilobases (kb) and 26 exons, is one of the largest genes in the human genome. The mature FVIII protein is a 2,332-amino-acid glycoprotein composed of 6 domains, A1-A2-B-A3-C1-C2, and is stabilized in plasma by non-covalent binding to von Willebrand factor (vWF).

The most frequent and important genetic variant causing classical hemophilia (hemophilia A) is the intron 22 inversion within the F8 gene, found in about 45~50% of severe patients. This inversion results from recombination between a repeat sequence within intron 22 of the F8 gene (int22h-1) and two homologous sequences located distally on the X chromosome (int22h-2, int22h-3); the middle of the F8 gene is inverted, separating exons 1~22 from exons 23~26, so that functional mRNA cannot be produced. The intron 1 inversion is another large rearrangement accounting for about 5% of severe cases.

Besides these two inversions, various variants have been reported, including point mutations (missense/nonsense), small·large deletions, small insertions, and splice-site variants. More than 2,000 pathogenic variants are registered in the international hemophilia A mutation database (HAMSTeRS). Variant type is closely related to severity and the risk of inhibitor development. Patients carrying large deletions, inversions, or nonsense variants that completely block protein production have a high risk of inhibitor development, whereas patients carrying missense variants with mild functional effects rarely develop inhibitors and tend to remain mild in severity.

For molecular diagnosis, intron 22 inversion testing is performed first; if negative, intron 1 inversion testing follows, and then the variant is identified by sequencing of the entire F8 gene (Sanger sequencing or next-generation sequencing, NGS). Genetic test results are essential for identifying carriers in the family, prenatal diagnosis, preimplantation genetic diagnosis, and predicting the risk of inhibitor development.

4. General epidemiology

Classical hemophilia (hemophilia A) is the most common severe congenital coagulation disorder, occurring worldwide at a frequency of about 1 per 5,000~10,000 males. It accounts for about 80% of all hemophilia (hemophilia A + B). According to the World Federation of Hemophilia (WFH) 2023 annual report, more than about 260,000 people worldwide are registered with hemophilia A, and the actual number of patients worldwide is estimated at more than about 400,000.

The distribution by severity is about 40~50% severe (FVIII < 1%), about 10~15% moderate (FVIII 1~5%), and about 30~45% mild (FVIII 5~40%). Because spontaneous mutations account for about 30%, the disease also occurs without a family history. It occurs at similar frequencies in all races and ethnic groups, with some regional differences in the spectrum of gene variants.

In Korea, according to the Korea Blood Disorder Registry (KBDR) and Health Insurance Review & Assessment Service (HIRA) statistics, there are about 2,300~2,500 registered hemophilia A patients. After registration for Special Copayment Reduction (V009) in Korea, a 10% copayment rate applies for 5 years. Systematic registration and treatment support are provided centered on the Korea Hemophilia Foundation and comprehensive hemophilia treatment centers nationwide, and recombinant FVIII products and emicizumab prophylaxis are covered by National Health Insurance.

Because of X-linked inheritance, males make up the vast majority. Female patients occur in carrier women with severely skewed X-chromosome inactivation, in women with Turner syndrome (XO) who have an F8 variant on the X chromosome, or in the homozygous state (very rare). In about half of carrier women, FVIII:C is reduced to the 40~60% level, and some of them may experience bleeding complications during surgery or delivery.

5. Pathophysiology

The pathophysiology of classical hemophilia (hemophilia A) stems from the loss of the key cofactor role played by FVIII in the blood coagulation cascade. When vascular injury occurs, the extrinsic pathway (tissue factor-FVII complex) is activated first and generates a small amount of thrombin, and this thrombin drives an amplification loop that activates platelets and coagulation factors (FV, FVIII).

Activated FVIIIa forms the intrinsic tenase complex (FIXa·FVIIIa·Ca²⁺·PS) together with FIXa and calcium ions on the phospholipid-rich platelet surface. This complex amplifies the reaction activating its substrate FX to FXa by up to several hundred thousand-fold compared with the FIXa-alone reaction. FXa forms the prothrombinase complex with FVa and converts prothrombin into large amounts of thrombin, and this thrombin converts fibrinogen to fibrin, forming a firm fibrin clot.

In hemophilia A, FVIII is absent or functionally defective, so the intrinsic tenase complex does not form or its function is severely reduced. As a result, even if a small amount of thrombin is generated through the extrinsic pathway, the amplification loop does not operate, thrombin generation is insufficient, and only a weak fibrin clot is formed. Primary hemostasis by platelets (platelet plug) proceeds normally, but because of FVIII deficiency this weak platelet plug is not reinforced with fibrin and is easily dissolved or broken by physical pressure.

Severity is determined by residual FVIII activity. Activity below 1% is severe, 1~5% moderate, and 5~40% mild. Joint cavities are particularly vulnerable sites where hemarthrosis recurs, because the synovium richly expresses TFPI (tissue factor pathway inhibitor), suppressing hemostasis via the extrinsic pathway. Recurrent hemarthrosis leads to hemophilic arthropathy, progressing through chronic synovial inflammation, hemosiderin deposition, enzymatic destruction of cartilage, and bone erosion.

6. Symptoms

The symptoms of classical hemophilia are identical to those of hemophilia A and are closely related to the severity classification based on FVIII activity.

Severe (FVIII < 1%): characterized by bleeding that occurs spontaneously without external stimuli. The most typical symptom is hemarthrosis. The knees, ankles, and elbows account for about 70~80% of all hemarthroses, and the hips, shoulders, and wrists can also be involved. Prodromal symptoms of hemarthrosis include tingling, warmth, and stiffness in the joint area, followed by rapid swelling, severe pain, and restricted joint motion. Muscle hematomas are also common; iliopsoas hematoma in particular can mimic intra-abdominal bleeding and delay diagnosis, and causes sensory abnormalities over the anterior thigh and weakened knee extension through femoral nerve compression. Intracranial hemorrhage is infrequent (1~2% per year) but is the most dangerous complication, and can occur from neonatal birth trauma, head injury, or spontaneously. Most severe patients are diagnosed before their first birthday.

Moderate (FVIII 1~5%): spontaneous bleeding is rare, but abnormally prolonged bleeding occurs after minor trauma or procedures. Joint bleeding also occurs, though less frequently than in severe disease, and some patients are first diagnosed in adolescence or adulthood.

Mild (FVIII 5~40%): most have no bleeding symptoms in daily life. Abnormal bleeding becomes apparent only with a clear trigger such as surgery, tooth extraction, or trauma. Diagnosis after incidental discovery of a prolonged APTT on preoperative testing in adulthood is most common in this group. Oral mucosal bleeding, epistaxis, hematuria, and gastrointestinal bleeding can also occur but are less specific than joint·muscle bleeding.

7. Signs

The clinical examination and laboratory signs of classical hemophilia are identical to those of hemophilia A.

Clinical examination findings: in active hemarthrosis, swelling, warmth, redness, tenderness, and reduced range of motion of the affected joint are observed. When chronic hemophilic arthropathy has progressed, joint deformity (flexion contracture, angular deformity), periarticular muscle atrophy, and joint instability may appear. Severe muscle hematomas may be accompanied by signs of adjacent nerve compression (sensory abnormalities, weakness, loss of deep tendon reflexes). Skin bruising is common, but petechiae or purpura are not characteristic (because platelet function is normal). Joint ultrasound or MRI shows findings of hemophilic arthropathy such as synovial thickening, hemosiderin deposition, cartilage damage, and bone cyst formation.

Laboratory findings: isolated APTT prolongation is the most characteristic laboratory sign. PT, platelet count, fibrinogen, and thrombin time are normal. Correction of APTT on a mixing study suggests factor deficiency; if it does not correct, the presence of an inhibitor or lupus anticoagulant is suspected. When reduced FVIII:C is confirmed, hemophilia A (classical hemophilia) is strongly suspected, and vWF:Ag and vWF:RCo are measured together to exclude von Willebrand disease (especially type 2N). The thrombin generation assay (TGA) is useful for comprehensively assessing FVIII concentration and functional clotting capacity.

8. Screening

Screening for classical hemophilia (hemophilia A) is considered in the following clinical situations: a bleeding tendency or a family history of hemophilia, a prolonged APTT found on routine preoperative coagulation testing, FVIII:C screening of carrier women, and newborn screening in families of hemophilia patients.

First-line coagulation screening panel: APTT, PT, platelet count, fibrinogen. In hemophilia A, the typical pattern is prolongation of APTT only, with the other items normal. Depending on the APTT reagent, APTT in mild hemophilia may be within the normal range, so FVIII:C is measured directly when there is clinical suspicion.

Direct FVIII:C measurement: measured by one-stage assay or chromogenic assay. 40% or more of the normal reference value is normal, 5~40% mild, 1~5% moderate, and below 1% severe. With some F8 variants (including patients using B-domain-deleted recombinant products), there may be a significant discrepancy between the one-stage and chromogenic methods.

Carrier screening: when a hemophilia A patient has been identified in the family, potential female carriers undergo both FVIII:C measurement and F8 genetic testing to determine carrier status. Targeted testing for the known familial variant is the fastest and most efficient genetic test. Carrier women whose FVIII:C is below the lower limit of normal (FVIII:C < 40%) may need prophylactic FVIII replacement during surgery or delivery.

Newborn screening: in male infants who are brothers of hemophilia patients or born to carrier mothers, FVIII:C is measured in cord blood immediately after birth. Because FVIII is near adult levels even in the neonatal period, measurement is possible. Prenatal diagnosis is performed by identifying the known familial F8 variant in fetal DNA via chorionic villus sampling at 11~14 weeks of gestation or amniocentesis at 15~18 weeks.

9. Diagnosis

Definitive diagnosis of classical hemophilia (hemophilia A) is made through stepwise testing.

Step 1: basic coagulation tests. On a panel consisting of APTT, PT, platelet count, and fibrinogen, isolated APTT prolongation is the first clue. Confirmation of a normal PT and normal platelet count suggests an intrinsic pathway defect.

Step 2: mixing study. Patient plasma and normal control plasma are mixed 1:1, and APTT is measured immediately and remeasured after 2 hours of incubation at 37°C. Immediate correction suggests factor deficiency. If correction does not occur or APTT becomes more prolonged after incubation, the presence of a time-dependent inhibitor (such as an FVIII inhibitor) or lupus anticoagulant is suspected.

Step 3: FVIII:C measurement and severity classification. FVIII:C is measured by one-stage clotting and chromogenic assays and classified as normal (≥40%), mild (5~40%), moderate (1~5%), or severe (<1%).

Step 4: differentiation from von Willebrand disease. In vWD type 2N (Normandy type), variants in the FVIII-binding domain of vWF reduce FVIII:C to 5~30%, which can be confused with hemophilia A. Differentiation is made by vWF:Ag (vWF antigen), vWF:RCo (ristocetin cofactor activity), and the vWF:FVIII binding assay. vWD type 1 can also be accompanied by a mild reduction in FVIII:C.

Step 5: Bethesda inhibitor assay. In patients with a treatment history or with a poorer-than-expected response to FVIII products, inhibitor titer is measured by the Bethesda assay or the Nijmegen modification. Below 0.6 BU/mL is classified as inhibitor-negative, and 5 BU/mL or higher as a high-titer inhibitor.

Step 6: F8 gene analysis. Intron 22 inversion testing (inverse PCR or long-range PCR) is performed first; if negative, intron 1 inversion testing follows, and then sequencing of the entire F8 gene (Sanger or NGS). Genetic test results are essential for identifying carriers in the family, prenatal diagnosis, and predicting the risk of inhibitor development.

10. Treatment

Treatment of classical hemophilia (hemophilia A) is identical to standard treatment of hemophilia A. Prophylaxis is the foundation of modern treatment, and immediate factor replacement is additionally given when bleeding occurs.

Desmopressin (DDAVP): in mild patients (FVIII:C 5~40%), this synthetic vasopressin analogue is given to release FVIII and vWF from storage pools in endothelial cells and platelets. It is given intravenously (0.3 μg/kg) or as a high-concentration nasal spray (150 μg/each nostril), and 30~60 minutes after administration FVIII:C rises to 3~6 times baseline. It is effective for minor surgery, dental procedures, and minor bleeding. Tachyphylaxis may occur after 2~3 consecutive doses, so repeated dosing is limited. Fluid restriction and prevention of hyponatremia are needed. It is not used in children under 2 years of age.

FVIII concentrates: there are standard half-life (SHL) recombinant FVIII products (octocog alfa, moroctocog alfa, turoctocog alfa, etc.) and extended half-life (EHL) recombinant FVIII products (efmoroctocog alfa-Fc fusion protein, damoctocog alfa pegol, rurioctocog alfa pegol, etc.). EHL products, given 1~2 times weekly, reduce the dosing burden compared with SHL products given 3 times weekly. Plasma-derived FVIII products (pd-FVIII) are also used safely after viral inactivation. The target FVIII:C is maintained at 1~3% or higher (ideally 5% or higher) during prophylaxis and replaced to 80~100% or higher in the perioperative period.

Emicizumab (Hemlibra): a bispecific monoclonal antibody that simultaneously binds FIXa and FX, functionally replacing the role of FVIIIa. It is given by subcutaneous injection, with options of once weekly, once every 2 weeks, or once every 4 weeks. The HAVEN trial series demonstrated a reduction of 80~90% or more in the annual rate of hemarthrosis. It is particularly advantageous in managing inhibitor patients because it can be used regardless of the presence of FVIII inhibitors. If active bleeding occurs during emicizumab treatment, rFVIIa is used, and combination with aPCC (FEIBA) is in principle avoided because of the risk of thrombosis.

Fitusiran: an siRNA-based subcutaneous injectable targeting antithrombin mRNA that suppresses antithrombin production in the liver, thereby reducing natural thrombin inhibition and enhancing coagulation. Prophylaxis is maintained with monthly subcutaneous injections, and it can be used in hemophilia A and B regardless of the presence of inhibitors.

Gene therapy: valoctocogene roxaparvovec (Roctavian) is the first approved (EU, 2022) AAV-based gene therapy for hemophilia A, delivering a B-domain-deleted F8 gene to hepatocytes using an AAV5 vector. A single intravenous dose can produce FVIII for several years and may replace continuous prophylaxis, but long-term follow-up data on long-term durability and efficacy in older patients continue to accumulate.

Inhibitor management: neutralizing antibodies (inhibitors) against FVIII products develop in about 25~30% of patients with severe hemophilia A. When an inhibitor is present, FVIII products lose their effect, and bypassing agents such as rFVIIa (NovoSeven) or aPCC (FEIBA) are used. Immune tolerance induction (ITI): a method of inducing immune tolerance by daily administration of high-dose FVIII (intermediate-dose or high-dose regimens, e.g., 200 IU/kg/day), with a success rate of about 70%. Emicizumab has been shown to have a prophylactic effect even in inhibitor patients, allowing prophylaxis to continue regardless of whether the inhibitor disappears.

11. Prognosis

The prognosis of classical hemophilia (hemophilia A) has changed dramatically over the past 60-odd years along with advances in treatment. Until the 1960s, the life expectancy of patients with severe hemophilia was only into their 10s~20s. Through advances in treatment — the introduction of FVIII concentrates in the 1970s, the spread of the prophylaxis concept in the 1980s, the advent of recombinant FVIII products in the 1990s, and the arrival of emicizumab in the 2010s — the life expectancy of hemophilia A patients receiving appropriate prophylaxis has now reached a level nearly equal to that of the general population.

Joint health is the most important factor determining long-term prognosis and quality of life. Patients who started prophylaxis in infancy (before 18 months or before the first bleed) can maintain near-normal joint status even as adults. In contrast, patients who grew up without prophylaxis or who had recurrent hemarthrosis may progress to chronic hemophilic arthropathy and experience complications such as chronic pain, loss of joint function, and joint replacement surgery.

Inhibitor development is the complication that most seriously threatens the prognosis of classical hemophilia. Neutralizing antibodies against FVIII develop in about 25~30% of patients with severe hemophilia A, and when a high-titer inhibitor develops, FVIII products have no effect at all and patients become dependent on bypassing agents. This leads to difficulty controlling bleeding, accelerated arthropathy, and reduced quality of life. The success rate of ITI is about 70%, and emicizumab has greatly improved the prognosis of inhibitor patients by enabling effective prophylaxis regardless of inhibitor status.

Transmission of HIV and hepatitis C through contaminated blood products in the 1980s was a great tragedy for hemophilia patients at the time, but today, with the use of blood products with established viral safety and recombinant products, this risk has virtually disappeared. With advances in new non-factor therapies such as fitusiran and concizumab and in gene therapy, the prognosis of classical hemophilia is expected to improve further.

12. Prevention

Prevention in classical hemophilia (hemophilia A) operates on three levels: prevention of bleeding itself, prevention of complications, and genetic prevention.

Primary prophylaxis: World Federation of Hemophilia (WFH) guidelines recommend starting regular prophylaxis in patients with severe hemophilia A before the first bleeding event or before age 2. The goal of prophylaxis is to continuously maintain the FVIII:C trough level at 1% or higher (ideally 5% or higher) to prevent spontaneous bleeding, especially hemarthrosis and muscle hematomas. Subcutaneous emicizumab prophylaxis is dramatically simpler than conventional intravenous FVIII infusion in route (subcutaneous) and frequency (once weekly, every 2 weeks, or every 4 weeks), making it very useful especially in infants and children with difficult venous access. Emicizumab can be used for prophylaxis regardless of the presence of inhibitors.

Secondary and tertiary prophylaxis: even in patients who have already had a first bleed or whose arthropathy has progressed, starting or intensifying prophylaxis can significantly suppress further bleeding and progression of joint damage. In patients with progressive arthropathy, physical therapy is combined with prophylaxis to preserve joint function as much as possible.

Inhibitor prevention: studies suggest that, in patients at high risk of inhibitor development (carriers of large deletion or inversion variants), the manner of first FVIII exposure affects inhibitor development. It has been hypothesized that starting first exposure as prophylaxis in a non-bleeding state and avoiding high-dose FVIII exposure during severe inflammation or when the immune response is activated may lower the risk of inhibitor development, but there are as yet no established prevention guidelines.

Genetic counseling and prenatal·preimplantation diagnosis: women identified as hemophilia A carriers can receive genetic counseling when planning pregnancy and determine the genetic status of the fetus through prenatal diagnosis (F8 gene analysis via CVS or amniocentesis) or preimplantation genetic testing (PGT-M). For delivery of a male infant with hemophilia, a delivery plan is established that includes avoiding vacuum and forceps delivery, avoiding scalp electrodes, measuring cord blood FVIII:C immediately after delivery, and, if possible, planning a cesarean delivery.

Lifestyle management: avoid vigorous contact sports and activities with a high risk of falls, and exercise with low joint stress such as swimming, cycling, and walking is recommended. Avoid aspirin·NSAIDs·antiplatelet agents, and minimize all intramuscular injections. Thorough oral hygiene reduces the need for dental procedures such as tooth extraction. Factor activity, inhibitors, and joint status are assessed periodically through regular follow-up at a specialized hemophilia center.

13. References

  1. Srivastava A, et al. WFH Guidelines for the Management of Haemophilia, 3rd ed. Haemophilia. 2020;26(S6):1-158.
  2. Biggs R, et al. Christmas disease: a condition previously mistaken for haemophilia. BMJ. 1952;2(4799):1378-1382.
  3. Mannucci PM, Tuddenham EG. The hemophilias—from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773-1779.
  4. Otto JC. An account of an hemorrhagic disposition existing in certain families. Med Reposit. 1803;6:1-4.
  5. Pool JG. Normal thromboplastin function of cold-insoluble globulin in hemophilia. Nature. 1964;203:312.
  6. Wood WI, et al. Expression of active human factor VIII from recombinant DNA clones. Nature. 1984;312(5992):330-337.
  7. Manco-Johnson MJ, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544.
  8. Oldenburg J, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2019;381(19):1811-1819.
  9. Gouw SC, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A. Blood. 2012;119(12):2922-2934.
  10. Ljung RC. Intracranial haemorrhage in haemophilia A and B. Br J Haematol. 2008;140(4):378-384.